期刊文献+

规范化癌痛护理干预对晚期癌痛患者负面情绪及生活质量的影响 被引量:2

下载PDF
导出
摘要 目的:观察规范化癌痛护理干预对晚期癌痛患者负面情绪及生活质量的影响。方法:将150例晚期癌痛患者随机分为对照组和观察组,每组75例。对照组给予常规护理,观察组在常规护理基础上给予规范化癌痛护理。比较两组患者预后情况。结果:干预4周后,观察组患者焦虑自评量表(SAS)评分、抑郁自评量表(SDS)评分均明显低于对照组(P<0.05);干预6个月后,观察组卡氏评分(KPS)评分均明显高于对照组(P<0.05)。结论:对晚期癌痛患者实施规范化癌痛护理,临床效果明显优于常规护理。
作者 马巧英
出处 《中国民间疗法》 2019年第11期88-89,共2页 China's Naturopathy
  • 相关文献

参考文献3

二级参考文献83

  • 1冯素文,来军,袁芳,赵志妹.影响妇科癌症患者家属生活质量的相关因素研究[J].中华护理杂志,2006,41(5):402-404. 被引量:62
  • 2中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2007版)[J].中国癌症杂志,2007,17(5):410-428. 被引量:232
  • 3Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifcn to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trim [J]. Lancet, 2013, 381(9869): 805-816.
  • 4Gray RG, Rea D, Handley K, et al. aTl'om: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6935 women with early breast cancer [ EB/OL ]. [ 2016-02-03 ]. http ://meetinglibrary. asco. org/content/112995-132.
  • 5LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone- receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trims [ J ]. Lancet, 2007, 369 (9574) : 1711-1723.
  • 6Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopansal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial [ J ]. Lancet Oncol, 2011, 12(7) : 631-641.
  • 7Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer [ J ]. N Engl J Med, 2014, 371(2) : 107-118.
  • 8Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopansal hormone-receptor-positive advanced breast cancer [ J ]. N Engl J Med, 2012, 366(6) : 520-529.
  • 9Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study I J]. J Clin Oneol, 2009, 27(27): 4530-4535,.
  • 10Howell A, Robertsan JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment[ J]. J Clin Oncol, 2002, 20(16) : 3396-3403.

共引文献85

同被引文献28

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部